KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Teva Pharmaceutical Industries (TEVA) over the last 14 years, with Dec 2024 value amounting to $14.0 million.

  • Teva Pharmaceutical Industries' Other Operating Expenses fell 133.33% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.0 million, marking a year-over-year decrease of 185.71%. This contributed to the annual value of $14.0 million for FY2024, which is 71.43% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Other Operating Expenses stood at $14.0 million for FY2024, which was down 71.43% from $49.0 million recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Other Operating Expenses peaked at $107.0 million during FY2022, and registered a low of $14.0 million during FY2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Other Operating Expenses averaged around $56.7 million, with its median value being $49.0 million (2023).
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Other Operating Expenses skyrocketed by 145.00% in 2021 and then crashed by 71.43% in 2024.
  • Teva Pharmaceutical Industries' Other Operating Expenses (Yearly) stood at $40.0 million in 2020, then skyrocketed by 145.00% to $98.0 million in 2021, then increased by 9.18% to $107.0 million in 2022, then slumped by 54.21% to $49.0 million in 2023, then crashed by 71.43% to $14.0 million in 2024.